Abstract. Neutral proleinases of neutrophilic polymorphonuclear leukocytes were fo llowed
Introduction
Hemodialysis therapy is associated with a considerable loss ofamino acids and glucose (I , 2] . On the other hand, hepatic gluconeogenesis is enhanced during renal insufficiency (3-51. Two possible causes of the reported increase in intradialytic protein catabolism [6) would be gluconeogenesis to replace glucose loss (during glucosefree dialysis) and protein breakdown to replace amino acid loss [7J. Glucose was fo und to be inefTective in reducing dialysis-induced catabolism. The average intradialytic urea generation was increased by 28% with glucose-free dialysis compared with 24 and 25%, respectiveIy, in the presence of glucose in the dialysate at a level of II or 26 mmol/I [7) . Furthermore, the replacement ofthe loss of am ino acids during dialysis by continuous amino acid infusion did not lower intradialytic protein catabolism, but appeared to increase it [6] .
Several studies have shown that proteinases participate in the protein catabolism ofpatients with hypercatabolic acute renal failure [8-1 1). Therefore, we evaluated the possibility ofenhanced protein breakdown by proteolytic enzymes liberated or activated during hemodialysis therapy. The rational for this is given by the high concentration of proteinases in neutrophil granulocytes and the well-known decrease of white blood cells followed by increased enzyme liberation after initiation of hemodialysis therapy -for review, see Heidland et al. (1 2). The aim of our present slUdy was twofold: (I) the cytochemical evaluation ofneutral proteinases ofneutrophilic polymorphonuclear (PMN) leukocytes of patients subjected to regular hemodialysis treatment (ROT), and (2) the detection of an increased liberation of the granulocytic proteinase elastase by measurement of the elastase-alproteinase inhibitor (E-aIPI) complex in plasma sampies of ROT patients. The plasma level of this complex was shown to be a suitable indicator of elastase liberation from activated or desintegrated granulocytes.
Material and Methods
We repon here the resuhs obtained in 12 chronically uremi c patients(9 men), age<l47.3 ± 4.0 years (mean ± SEM , range 22-66), undergoing ROT for 4 1.3 ± 11.6 months (range 4-124). Hemodia· lysis was performed three limes per weck for 5 h with Gambro Lun· dia Optima and a glucose-frec bath containing acetate. 4 patients suffered from diabetic glomerulosclerosis, 2 from po1ycystic kidney degeneration and 6 from chronic glomerulone phrit is. Blood cells were counted by an electronic counter (Coulter·Counter-M odel B). Fun her blood constituents were determined as folIows: creatinine 11.5 ± 0.8 mgldl (range 7.2-16.9); urea nitrogen 76.9 ± 4.7 mgldl (range 54-105); hemoglobin 9.2 ± 0.5 gldl (range 7.4-13.2), and filt. l . 8100d smear from a health y subjccl. Fixation was performe<! using formaline sublimate. Thc smear was incubated with 0.25 M NaQ borate buffer (pH 8.5) for 120 min 31 37 · Cand stained wit h col1oidal ira n. hcmatocrit 30.3 ± 1.7% (range 23.7-42.5). Plasma sampies were oblained by withdrawing 4.5 ml ofvenous blood in ta plastic syri nges oontaining 0.5 ml of sodium ci trate (2.2g/100ml disti1led water). Plasma was scparaled from blood within 30 min after sampIe calleelion 10 pre vent leakage of Icu kocylc co nstituents. Thc plasma specimcns were Store<! at -70·C until aSS3yed.
Thc inhibilOry acti vi ty of anlilhrombin 111 (AT 111) againSI thrombin was detcrmined using the Ihrombin-specific chromogenie substrate S·2238 (Deutsche Kahi. Munich. FRG). Thc inhibilory activit)' of the al-proteinase inh ibi tor (aI PI = a l-a ntitrypsin) was measured with a commercial test system (Boehri nger. Mannheim, FRG). Plasma conccnlrations of o, j-macroglobulin (alM). a lP!. albumin as welt as com plcmenlcomponents Cl and C. were eval uated by a radial immunodiffusion technique with standard ized immunodiffusion platcs (lkhringwerke AG. Marburg. FRG).
Quantitati ve estimation of the plasma le vels of the E-aI PI complex was ca nied out with a highly se nsitive enzyme-linked immunoassay [13] . Protcolytic activi ty of the plasma sa mpIes was measured using azocasein as substrate as previousl y described [9. 14] .
Proteinase activit y o fthe neulroph ilic PMN leukoc:yles was observed with the cytochemicaltest of KleJst'fI [15] .
Res ults were ex presscd as mean va lues :t SEM. Statistical evalu· ation was performed by Ihe Student's ttest.
Results
The cytochemicaltest of KIessen (15 J was used to evaluate thc activity of neutrophilic PM N leukocyte proteases. These enzymes are released from the PM N neutro phi ls of healthy subjects in blood smears fo llowing incubation wi th sodium chloride borate buffer. Proteolytic activity is revealed by a ring-shaped area around each neutrophil (fi g. 1). T hi s halo effect is due to erythro- The effect of hemodialysis on leukocytes, plasma levels ofthe E-a IPI complex as weil as on (t IPI activilY and concentration is shown in table I. Therc was a decrcase of wh itc blood cells 10 min (2 l.l %; n.s.) and 30 min (41.1 %; p < 0 .(0 1) after in itiation of hemodialysis therapy. We observed maximum levels ofthe plasma E-(tI PI complex after 3 h (+409%; p < 0.00 I). However, plasma (tI PI activity and concentrat ion were unchanged d uring hemodialysis therapy.
The plasma levels of a 2M (before dialysi5, 244 ± 17; after 3 h of dialysis therapy, 257 ± 3 1 mgld l), AT 111 (91. 3 ± 2.5 vs. 95.2 ± 4.3 %), complement componcn ts Cd l 54 ± 6V5. 160 ± 8mgldl)orCd61.7 ± 3.8vs. 64.6 ± 3.7 mgld l) remained also unchanged . Dialysis therapy was performed to maintain a constant body weight d uring the fi rst 3 h. Plasma albumin concentration (3.77 ± 1. 12 vs. 3.88 ± 0. 14 g1dl) or hematocrit (30.3 ± 1.7 vs. 3 1.3 ± 2.0 %) wcre in thc sa me range be fore and 3 h afte r start ing hemodialysis Ihcrapy.
Using azocasein as a substrate, the proteolytic activity ofthc plasma sam pies was significan tly higher (+ 244 %; p < 0.01) beforc dialysis therapy compared wit h plasma sam pies of healthy cont rols (0.052 ± 0.004 U/ mg protein). During dialysis therapy. however, there was apermanent decrease ofthi s plasma proteinase acti vity (0. 127 ± 0.0 19 vs. 0.037 ± 0.007 U/ mg; -7 1%; p < 0.00 1; 
Diseussion
It has been shown recently that glucose in the dialysate (7] as weil as continuous amino acid infusion [6J are ineffeclive in preventing thc p3thological calabolic cvents observed during hemodialysis. The pathogenesis of hemodia lysis-induced protein catabolism remains so far undear. One pathogenetic factor could bc Ihe release o f granulocyte proteinases after starting hemodialysis therapy. Craddock et al. [16] ha ve de monstratcd hemodialysisinduced leukopenia and pulmonary vascular leukoSlasis resulting from complement activation by dialyzer cellophane membranes. Neutrophil granulocytes contain a broad variety of agents that are involved in the defence and digestion of in vading microorganisms [1 7J. These include clastase [1 7, 18J, cathepsin G , cathepsi n B, cathepsin 0 and collagenasc [1 9-24). Lysosomal proteinases are not exclusively restricted 10 their intracellular compartment, the lysosomes. They may be released in tra-as weil as extracell ularly during phagocytosis, exposure to antigen-antibody complexes, complement components and toxic substances such as endotoxi ns or during cell death [25 , 26) . Especially under pathological conditions massive release ofprot eases and other lysosomal factors may occur. They might cause tissue injury [27 , 28J and consumption of plasma proteins by unspeci fic proteolytic degradation as soon as the levels ofthe controlling proteinase inhibitors in plasma and tissues are insufficient [29] .
Granulocyte elastase is the most potent candidate for unspecific degradation because of its broad substrate specificity and the large amount present in the PM N [32] . In vitra elastase rapidly inacti vates fibrinogen [33, 34] and several other clotting factors (35, 36] . h also causes a limited degradation o fth e third and fifth factor ofhuman complement [3 7, 38] .
Granulocyte elastase could be released during hemodia lysis due to the contact of blood cells wüh the blood Hnes and the dialyzer membrane (euprophane). Such contaet may result in a so-ealled ' frustrated phagocytosis' known to be associatcd with an extracellular release of Iysosomal proteinases. The redueed proteolytic acti vity of PMN leukocytes in blood smears obtained 30 min after onse! ofhemodialysis and the eoncomitant inerease of E-U1PI plasma levels may be regarded as possible indicalors of this 'escape' reaction. O n the other hand, proteinase release due 10 cell death must be also taken into account. Since, however, leukopenia docs not strictly parallel the inerease of the E-UIPI levels during hemodialysis, pulmonary vascular leukostasis resulting from com plement activation by dialyzer cellophane membranes may be an additional source of local lysosomal enzyme release (1 6J. This event could indeed be responsible for the delayed release of elastase into the circulation. Although plasma activity and concentrat ion OfU 1Pl. the dominating elastase inhibitor [39] , were unchanged during hemodialysis therapy (table I) , the liberation of granulocytic elastase together with other Iysosomal enzymes, primarily wühin the lung, might lead to a repeated local proteinase-proteinase inhibitor imbalance (40) (41) (42) thus favoring pulmonary disease in long-tenn ROT patients. The deleterious release of granulocytic proteinases during hemodialysis is partly counteracted by the diminution of'unspecific' proteolytic (azocasei n-hydrolyzing) activity accumulated in plasma in thc dialysis-free interval . Thc decrease of Ihis unspecific proteolytic activity during hemodialysis rnigh! be caused by the removal of yet unidentifi ed low molecular weight factors. Such fac--tors could stimulate the activation of proenzymes (e.g. plasma prokallikrein) or thc release oflysosomal proteinases into thc plasma of untreated patients. They rnigh! also be responsible for the stimulation of phagocytosis and/or increased protein breakdown within thc cells.
Characterization of thc azocasein-splitting activity using more specific substrates might be a helpful tool in evaluating thc origin and nature of Ihis proteolytic effecl.
Summarizing our results, we could dearly demonstrate that hemodialysis therapy is still connected with considerablc side effects probably duc to the contacl of white blood cells with the dialyzer cellophane membranes. Improvement of such membranes leading 10 reduced liberation of proteolytic cell constitucnts should, thcrcfore, en hance the positive effects of hemodialysis thcrapy.
